Arecor Therapeutics PLC Arecor announces AT278 presentation at EASD 2024

RNS Number : 6089C

Arecor Therapeutics PLC

03 September 2024

 

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR ANNOUNCES ORAL PRESENTATION OF POSITIVE AT278 PHASE 1 CLINICAL DATA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 2024

 

·    Late-breaking presentation will detail data from Phase I clinical trial of ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in overweight and obese people with type 2 diabetes

 

Cambridge, UK, 3 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that its abstract titled "Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart AT278 U500 in overweight and obese people with type 2 diabetes" has been selected as a late-breaking oral presentation at the 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will be held from 9-13 September 2024 in Madrid and online.

 

The presentation will take place on Wednesday 11 September during the SO 03 Presentation Session "One size down, three (or more) to go".

 

Oral Presentation:          Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart AT278 U500 in overweight and obese people with type 2 diabetes

Presenting Author:        Professor Thomas Pieber, Medical University of Graz, Austria

Presentation Number:  LBA 53, Station 18                           

Date and Time:               Wednesday 11 September, 12:45-13:45 (Central European Time)

 

AT278 (500 U/mL) is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence, a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "The recent clinical results from our second Phase I study with AT278 demonstrated superiority (PK/PD) over NovoRapid® and Humulin® R U-500 in Type 2 diabetics with a high BMI. This set of data, which builds on positive results from a previous clinical study in Type 1 diabetic patients, shows that AT278 has the potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation truly miniaturised, longer-wear insulin pumps, a key focus for patients, physicians and the industry. We look forward to Professor Thomas Pieber, Principal Investigator for the ARE-278-104 clinical trial, sharing the latest data behind this next generation insulin candidate with scientific colleagues in Madrid."

 

About the EASD

The European Association for the Study of Diabetes (EASD) is a non-profit, medical scientific association, founded in 1965 to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. EASD holds its Annual Meeting in a different European city each year with more than 15,000 delegates from over 130 countries attending. The scientific programme includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field.

-ENDS-

 

 

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Panmure Liberum Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
WG Partners LLP (Financial Advisor)
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang	Tel: [phone]
ICR Consilium
Chris Gardner, David Daley, Lindsey Neville	Tel: [phone] Email: [e-mail]

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

 

For further details please see our website, www.arecor.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGZGGLNZGGDZM